Understanding Drug Effect Heterogeneity to Guide the Design of Precision Pharmacotherapy in Hospitalized Patients

  • September 13, 2019 from 12:00-1:00 pm
  • In-person: Christiana Hospital, Room 1100
  • On-line: Watch live at https://bluejeans.com/361095905
  • Or join meeting ID 361095905 on the BlueJeans app on your smartphone or tablet

Lunch will be served. Please RSVP.

Hospitalization represents a period of increased risk for adverse drug events. Acute illness renders hospitalized patients especially vulnerable to drug toxicity, while also contributing to treatment effect heterogeneity. In addition, polypharmacy is common, with 50-75% of patients exposed to potential drug-drug interactions during admission. Consequently, adverse drug events remain a leading cause of harm in hospitalized patients. This presentation will demonstrate how the electronic health record can be leveraged to study drug effects in hospitalized patients and guide the design of novel precision pharmacotherapy interventions.

Meet the Speaker

Dr. Miano is an Instructor of Epidemiology at the University of Pennsylvania Perelman School of Medicine, and a Surgical Critical Care Pharmacist at the Hospital of the University of Pennsylvania. He received a Doctor of Pharmacy Degree from Virginia Commonwealth University and Doctoral degree in Epidemiology from the University of Pennsylvania. He is an elected fellow of the American College of Critical Care Medicine and an Associate Editor of BMC Pharmacology and Toxicology. His research leverages electronic health record data to study drug safety and comparative effectiveness in the hospitalized population. In particular, his work focuses on understanding the key sources of drug effect heterogeneity, including pharmacogenetics, drug-drug interactions, and drug-disease interactions. His long term goal is to incorporate new knowledge of these mechanisms into the design of novel precision medicine interventions, including clinical decision support tools and treatment pathways.

This activity has been approved for AMA PRA Category 1 Credit

Stay Connected

Join the ACCEL newsletter and keep up to date with the latest news, events and funding opportunities!